ZTS

In the most recent trading session, Zoetis (ZTS) closed at $78.8, indicating a +1.29% shift from the previous trading day.

Is ZTS a good stock to buy? We came across a bullish thesis on Zoetis Inc. on D Invests’s Substack.

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) just received FDA approval for Convenia RTU for Dogs, a long acting injectable antibiotic for skin infections, raising fresh questions about how its expanding canine portfolio might influence investor expectations.

Zoetis has seen its share price fall sharply in recent years, so the key issue now is whether the current valuation still lines up with what the business is earning.

Zoetis (NYSE:ZTS) received FDA approval for Convenia RTU for Dogs, a single-dose antibiotic for canine skin infections. The new formulation is designed for a smaller injection volume and can be used across a wide range of dog sizes.

Zoetis will release its third-quarter earnings next week, and analysts anticipate a low double-digit profit dip.

For questions about this article or underlying research, email [email protected].

Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on IDXX.

For questions about this article or underlying research, email [email protected].

Zoetis offers diversification and stability, while ImmuCell boasts stronger sales growth and expansion potential.